A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma

References

• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–2306.
   PubMed Web of Science ®Google Scholar
• Moullet I, Salles G, Ketterer N, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9: 1109–1115.
   PubMed Web of Science ®Google Scholar
• Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–1692.
   PubMed Web of Science ®Google Scholar
• Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987–1994.
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Pagel H, Wolff M, et al. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992;50:301–308.
   PubMed Web of Science ®Google Scholar
• Hamai Y, Hihara J, Taomoto J, et al. Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg 2014;38:2046–2051.
   PubMed Web of Science ®Google Scholar
• Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist 2000;5:13–18.
   Google Scholar
• Rutkowski T, Suwinski R, Idasiak A. The prognostic value of hemoglobin concentration in postoperative radiotherapy of 835 patients with laryngeal cancer. Int J Radiat Oncol Biol Phys 2007;69: 1018–1023.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–854.
   Google Scholar
• Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855–864.
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009;15:2905–2912.
   PubMed Web of Science ®Google Scholar
• Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol 2012;96:617–623.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol 2014;31:860.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998;16:70–77.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182–190.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612–618.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 2013;119:348–355.
   PubMed Web of Science ®Google Scholar
• Huang H, Lin Z, Lin X, Cai Q, Xia Z, Jiang W. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma 2011;52:1041–1048.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   Web of Science ®Google Scholar
• Dainiak N, Kulkarni V, Howard D, et al. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 1983;51:1101–1106.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang WD, Geng QR, et al. Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma. PLoS One 2014;9:e94637.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhu JY, Liu CC, et al. Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma. Med Oncol 2015;32:370.
   PubMed Web of Science ®Google Scholar
• Wang L, Liao DZ, Zhang J, et al. Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. Med Oncol 2013;30:723.
   PubMed Web of Science ®Google Scholar
• Henke M, Bechtold C, Momm F, et al. Blood hemoglobin level may affect radiosensitivity-preliminary results on acutely reacting normal tissues. Int J Radiat Oncol Biol Phys 2000;48:339–345.
   PubMed Web of Science ®Google Scholar
• Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113–117.
   PubMed Web of Science ®Google Scholar
• Evans SM, Jenkins WT, Shapiro M, et al. Evaluation of the concept of “hypoxic fraction” as a descriptor of tumor oxygenation status. Adv Exp Med Biol 1997;411:215–225.
   PubMed Web of Science ®Google Scholar
• Li YX, Wang H, Jin J, et al. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1809–1815.
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18:54–63.
   PubMed Web of Science ®Google Scholar
• Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 2008;83: 795–799.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29: 4410–4416.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834–1839.
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931–3937.
   PubMed Web of Science ®Google Scholar
• Jiang L, Li P, Wang H, et al. Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type. Med Oncol 2014;31:218.
   PubMed Web of Science ®Google Scholar
• Li YJ, Li ZM, Xia Y, et al. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One 2013;8:e64158.
   PubMed Web of Science ®Google Scholar
• Wang KF, Chang BY, Chen XQ, et al. A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE/IIE upper aerodigestive tract extranodal NK/T cell lymphoma, nasal type. Med Oncol 2014;31:318.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Konishi I. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer]. Gan To Kagaku Ryoho 2014;41:1071–1076.
   PubMedGoogle Scholar
• Li P, Jiang L, Zhang X, et al. CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. BMC Cancer 2014;14:890.
   PubMed Web of Science ®Google Scholar